An Austrian research company dedicated to the development of immune diagnostics and vaccines
Viravaxx develops vaccine candidates against hard-to-treat viral diseases, such as infections with Hepatitis B. Our lead product is VVX001, a clinical phase II Hepatitis B vaccine candidate. Beside vaccines, Viravaxx also develops high resolution serum immune diagnostics based on microarray technology.
Our company’s advances in developing early vaccine constructs against SARS-CoV-2 and in setting up a SARS-CoV-2 Blocking Antibody Test have raised attention within the worldwide scientific community. To this, India’s well known online journal Future Medicine has conducted a recent interview with Viravaxx: